Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025 ...

It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...

Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it. Now, an alliance between Novartis and genetic testing specialist 23andMe is ...

Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment ...

The following is a summary of “High Density Lipoproteins Associate with Age-Related Macular Degeneration in the All of Us Research Program,” published in the January 2025 issue of Ophthalmology by ...

The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.

Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...

Lipoprotein (a) [Lp(a)] is considered pro-atherosclerotic, pro-inflammatory, pro-thrombotic, and anti-fibrinolytic. Lipoprotein(a) levels >50 mg/dL are associated with an increased risk of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

After hours: February 7 at 5:29:10 PM EST Loading Chart for UAN ...

After hours: February 7 at 4:09:01 PM EST Loading Chart for GLP ...